239 related articles for article (PubMed ID: 1727618)
1. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
Varga J; Uitto J; Jimenez SA
Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
Sternberg EM
Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
[TBL] [Abstract][Full Text] [Related]
3. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
Varga J; Jimenez SA; Uitto J
J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
[TBL] [Abstract][Full Text] [Related]
4. 1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant.
Yamaoka KA; Miyasaka N; Inuo G; Saito I; Kolb JP; Fujita K; Kashiwazaki S
J Clin Immunol; 1994 Jan; 14(1):50-60. PubMed ID: 8132737
[TBL] [Abstract][Full Text] [Related]
5. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead.
Sidransky H
Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518
[TBL] [Abstract][Full Text] [Related]
7. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology.
Martin RW; Duffy J; Engel AG; Lie JT; Bowles CA; Moyer TP; Gleich GJ
Ann Intern Med; 1990 Jul; 113(2):124-34. PubMed ID: 2360751
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
[TBL] [Abstract][Full Text] [Related]
9. Effect of L-tryptophan products on function of human eosinophils: investigation of the causal mechanisms of eosinophilia myalgia syndrome associated with L-tryptophan products.
Saito H; Miyamoto T
Int Arch Allergy Immunol; 1996; 111 Suppl 1():37-42. PubMed ID: 8906111
[TBL] [Abstract][Full Text] [Related]
10. The eosinophilia-myalgia syndrome and eosinophilic fasciitis.
Jimenez SA; Varga J
Curr Opin Rheumatol; 1991 Dec; 3(6):986-94. PubMed ID: 1772754
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination.
Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ
J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795
[TBL] [Abstract][Full Text] [Related]
12. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
Zangrilli JG; Mayeno AN; Vining V; Varga J
Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
[TBL] [Abstract][Full Text] [Related]
13. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
[TBL] [Abstract][Full Text] [Related]
14. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
[TBL] [Abstract][Full Text] [Related]
15. EBT, a tryptophan contaminant associated with eosinophilia myalgia syndrome, is incorporated into proteins during translation as an amino acid analog.
Buss WC; Stepanek J; Bankhurst AD; Mayeno AN; Pastuszyn A; Peabody D
Autoimmunity; 1996; 25(1):33-45. PubMed ID: 9161698
[TBL] [Abstract][Full Text] [Related]
16. L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.
Barth H; Klein R; Berg PA
Clin Exp Immunol; 2001 Nov; 126(2):187-92. PubMed ID: 11703359
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer.
Slutsker L; Hoesly FC; Miller L; Williams LP; Watson JC; Fleming DW
JAMA; 1990 Jul; 264(2):213-7. PubMed ID: 2355442
[TBL] [Abstract][Full Text] [Related]
18. [L-tryptophan and the eosinophilia-myalgia syndrome--consequences for artificial nutrition?].
Bässler KH
Infusionstherapie; 1991 Feb; 18(1):5-10. PubMed ID: 1903129
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Silver RM
Curr Opin Rheumatol; 1993 Nov; 5(6):802-8. PubMed ID: 8117543
[TBL] [Abstract][Full Text] [Related]
20. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan.
Hertzman PA; Blevins WL; Mayer J; Greenfield B; Ting M; Gleich GJ
N Engl J Med; 1990 Mar; 322(13):869-73. PubMed ID: 2314421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
